论文信息 - An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928). - 字舞流文

An open-label phase II trial of dabrafenib (D) in combination with trametinib (T) in patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC; BRF113928).

H. Groen | J. Rigas | S. Novello | D. Planchard | J. Mazières | F. Barlesi | P. Souquet | B. Besse | T. Kim | E. Quoix | C. Baik | Allison Upalawanna | A. D'Amelio | Pingkuan Zhang | B. Mookerjee | B. Johnson